Ex-Dendreon chief Mitch Gold steers his way back to the public markets, looking to jumpstart a new clinical program
Mitch Gold is coming back to the helm of a public biotech company.
The former Dendreon CEO — and current venture capitalist — who was forced out of that company as Provenge slowly derailed, is getting back into the public eye with considerably less fanfare this time around.
After Nivalis’ drug failed in a disastrous attempt to come up with an add-on to Vertex’s cystic fibrosis combo, about the only thing left after the inevitable slash and burn on staff and costs was a virtually empty public shell.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
